Ultragenyx Pharmaceutical (RARE) Goodwill (2017 - 2026)

Ultragenyx Pharmaceutical (RARE) has 10 years of Goodwill data on file, last reported at $44.0 million in Q1 2026.

• Quarterly Goodwill fell 0.91% year-over-year to $44.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $44.0 million (down 0.91% YoY) and the FY2025 annual result came in at $44.0 million, changed 0.0% from the prior year.
• Goodwill held at $44.0 million in Q1 2026 per RARE's latest filing, from $44.0 million in the prior quarter.
• Across five years, Goodwill topped out at $44.4 million in Q1 2022 and bottomed at $44.0 million in Q4 2024.
• The 5-year median for Goodwill is $44.4 million (2022), against an average of $44.3 million.
• The widest annual swing landed in 2022, when Goodwill changed 0.0%; it then slipped 0.91% in 2024.
• Tracing RARE's Goodwill over 5 years: stood at $44.4 million in 2022, then changed by 0.0% to $44.4 million in 2023, then slipped by 0.91% to $44.0 million in 2024, then changed by 0.0% to $44.0 million in 2025, then changed by 0.0% to $44.0 million in 2026.
• Per Business Quant, the three latest RARE Goodwill figures stand at $44.0 million (Q1 2026), $44.0 million (Q4 2025), and $44.4 million (Q3 2025).

Peer Comparison